| All Releases
|
|---|
 |
Cytori Provides Business Update; Reports First Quarter Results
May 9, 2012
|
23.6 KB
|
| |
SAN DIEGO, CA -- (Marketwire) -- 05/09/12 --
During the first quarter of 2012, Cytori Therapeutics (NASDAQ: CYTX) advanced its cardiac cell therapy product pipeline, grew the commercial business, and strengthened operational and financial performance, which encompasses management of expenses, strategic partnerships, and regulatory approvals. O...
|
|
|
May 2012 Shareholder Letter
May 9, 2012
|
565.2 KB
|
| |
May 9, 2012
Dear Investors,
Management is focusing on delivering strong results in each of our three business areas and achieving the goals established for 2012, setting the foundation for leadership and growth in the cell therapy field. The following will detail accomplishments and updated information in each of the thre...
|
|
|
Cytori to Webcast First Quarter Financial Results May 9
Apr 27, 2012
|
9.6 KB
|
| |
SAN DIEGO, CA -- (Marketwire) -- 04/27/12 --
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Wednesday, May 9, 2012 at 5:00 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.888.208.1815
...
|
|
|
Video Webcast on the Future of Cardiac Medicine
Apr 3, 2012
|
8.1 KB
|
| |
An educational course on cardiac cell therapy is now available online (http://bit.ly/HC8c2W; free registration required), which covers the following topics:
? Gaps in treatment of chronic myocardial ischemia patients;
? Potential role of cell therapy, in particular for chronic myocardial ischemia; and
? The role adipose-derived ste...
|
|
|
Cytori Breast Reconstruction Cell Therapy Trial Results Published
Mar 19, 2012
|
15.3 KB
|
| |
ZUG, SWITZERLAND and SAN DIEGO, CA -- (MARKET WIRE) -- 03/19/12 --
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology.
RESTORE-2 is a 71 patient multi-center, prospective clinical trial using autologous adipose-derived regenerati...
|
|
|
FDA Grants Cytori 510(k) Clearance for Puregraft(R) 850
Mar 16, 2012
|
11.9 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 03/16/12 --
Cytori (NASDAQ: CYTX) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Puregraft® 850 System for body contouring using a patient's own fat. The Puregraft® 850 product line extension provides optimized and sterile processing of up to 850 mL of tissue, ...
|
|
|
Cytori Provides Strategic Outlook, Near Term Objectives and Reports Year-End 2011 Results
Mar 8, 2012
|
25.4 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 03/08/12 --
In 2011, Cytori Therapeutics (NASDAQ: CYTX) achieved important objectives towards validating Celution® technology in multiple large market indications, clarified the U.S. cardiovascular pathway with FDA, and raised cash to fund 2012 objectives. In particular, the Company reported positive long...
|
|
|
March 2012 Shareholder Letter
Mar 8, 2012
|
18.1 KB
|
| |
Dear Investors,
Our plan for increasing shareholder value in 2012 is focused on three areas:
- Advance our cardiovascular pipeline
- Grow our commercial business toward profitability while establishing the elements for market access
- Achieve strategic partnerships to grow our business and strength...
|
|
|
Cytori to Webcast Year End Financial Results March 8
Feb 23, 2012
|
10.3 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 02/23/12 --
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Thursday, March 8, 2012 at 5:00 PM Eastern Time.
Prior to the webcast at approximately 4:05 PM Eastern Time on March 8, Cytori will issue its yea...
|
|
|
Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA
Jan 30, 2012
|
12.8 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 01/30/12 --
Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the ATHENA trial. ATHENA will investigate the use of the Celution® System, an innovative medical device to prepare adipose-derived stem and regenerative cells (ADRCs) t...
|
|
|
Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori's APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function
Jan 24, 2012
|
15.1 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 01/24/12 --
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Resea...
|
|
|
Cytori Announces Presentations at Biotech Showcase on Jan 9th and 10th
Jan 5, 2012
|
11.0 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 01/05/12 --
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will webcast their corporate presentation at the Biotech Showcase at 4:00 PM PT on Monday, January 9 in San Francisco. The webcast may be accessed under "Webcasts" in the Investor Relations section of the Company's website, www.cytori.com. The webcast can be...
|
|
|
Cytori Completes IDE Filing for Chronic Myocardial Ischemia ATHENA Trial of the Celution® System
Dec 19, 2011
|
12.3 KB
|
| |
SAN DIEGO, CA -- (MARKETWIRE) -- 12/19/11 --
Cytori Therapeutics (NASDAQ: CYTX) filed its Investigational Device Exemption (IDE) application to begin a clinical trial of the Company's Celution® System for chronic myocardial ischemia (CMI).
ATHENA is a device-based safety and feasibility trial (Phase I/II) to investigate the use...
|
|
|
Cytori's Celution(R) One Receives European CE Mark Approval
Nov 30, 2011
|
11.1 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 11/30/11 --
Cytori's (NASDAQ: CYTX) Celution® One System, the next-generation device of the Company's Celution® platform, has been granted CE Mark approval. Celution® One is tailored specifically for the hospital as a platform device with potential life-critical applications across multiple spec...
|
|
|
Cytori Therapeutics Announces Participation in the 2011 Stem Cell Meeting on the Mesa's Investor and Partnering Forum
Nov 28, 2011
|
12.0 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 11/28/11 --
Cytori Therapeutics (NASDAQ: CYTX) will present at the 2011 Stem Cell Meeting on the Mesa's Investor and Partnering Forum on December 1. In addition, CEO Christopher Calhoun will participate on a regenerative medicine business panel also on December 1.
Cytori's presentation and panel ...
|
|
|
Cytori to Webcast Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011
Nov 10, 2011
|
10.4 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 11/10/11 --
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will webcast their corporate presentation at the Lazard Capital Markets 8th Annual Healthcare Conference at 9:30 AM (ET) on Wednesday, November 16, 2011 in New York.
The webcast may be accessed under "Webcasts" in the Investor Relations sectio...
|
|
|
Cytori Reports Third Quarter Business Update and Financial Results
Nov 3, 2011
|
24.0 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 11/03/11 --
Cytori Therapeutics (NASDAQ: CYTX) today is reporting its third quarter 2011 business update and financial results.
Product revenues for the third quarter of 2011 increased to $2.1 million, compared to $1.5 million in the third quarter of 2010. Gross profit increased to $1.2 million w...
|
|
| |
November 2011 Shareholder Letter
Nov 3, 2011
|
548.2 KB
|
|
Cytori to Webcast Third Quarter Financial Results November 3
Oct 26, 2011
|
10.2 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 10/26/11 --
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and quarterly business update on Thursday, November 3, 2011 at 5:00 PM Eastern Time.
Prior to the webcast at approximately 4:05 PM Eastern Time on November 3, Cytori will issue its t...
|
|
|
Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement
Sep 23, 2011
|
11.3 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 09/23/11 --
Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution® System agreement with Apollo Hospitals, one of Asia's largest private healthcare groups, to offer the technology initially at select cosmetic surgery centers in India.
"At Apollo Hospitals, we pride ourselves on int...
|
|
|
Blog
StockTwits
Twitter
SlideShare
Events